|Bid||3.05 x 2000|
|Ask||3.47 x 2000|
|Day's Range||3.11 - 3.28|
|52 Week Range||1.93 - 3.77|
|PE Ratio (TTM)||7.29|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.
PDL BioPharma is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.